Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
Stock Information for Aravive Inc.
Loading
Please wait while we load your information from QuoteMedia.